Quantification of HTLV-I proviral load in experimentally infected rabbits by Zhao, Tong-Mao et al.
BioMed  Central
Page 1 of 10
(page number not for citation purposes)
Retrovirology
Open Access Research
Quantification of HTLV-I proviral load in experimentally infected 
rabbits
Tong-Mao Zhao1, Bishop Hague1, David L Caudell2, R Mark Simpson2 and 
Thomas J Kindt*1
Address: 1Molecular and Cellular Immunogenetics Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 
Bldg #50, Room 5515, 50 South Drive, Bethesda, MD 20892, USA and 2Molecular Pathology Unit, Center for Cancer Research, National Cancer 
Institute, National Institutes of Health, Bldg #37, Room 2002, 37 Convent Drive, Bethesda, MD 20892, USA
Email: Tong-Mao Zhao - tzhao@niaid.nih.gov; Bishop Hague - bhague@niaid.nih.gov; David L Caudell - caudelld@mail.nih.gov; R 
Mark Simpson - simpsoma@mail.nih.gov; Thomas J Kindt* - tkindt@niaid.nih.gov
* Corresponding author    
Abstract
Background: Levels of proviral load in HTLV-1 infected patients correlate with clinical outcome
and are reasonably prognostic. Adaptation of proviral load measurement techniques is examined
here for use in an experimental rabbit model of HTLV-1 infection. Initial efforts sought to correlate
proviral load with route and dose of inoculation and with clinical outcome in this model. These
methods contribute to our continuing goal of using the model to test treatments that alleviate virus
infection.
Results: A real-time PCR assay was used to measure proviral load in blood and tissue samples
from a series of rabbits infected using HTLV-1 inocula prepared as either cell-free virus particles,
infected cells or blood, or by naked DNA injection. Proviral loads from asymptomatically infected
rabbits showed levels corresponding to those reported for human patients with clinically silent
HTLV-1 infections. Proviral load was comparably increased in 50% of experimentally infected
rabbits that developed either spontaneous benign or malignant tumors while infected. Similarly
elevated provirus was found in organs of rabbits with experimentally induced acute leukemia/
lymphoma-like disease. Levels of provirus in organs taken at necropsy varied widely suggesting that
reservoirs of infections exist in non-lymphoid organs not traditionally thought to be targets for
HTLV-1.
Conclusion: Proviral load measurement is a valuable enhancement to the rabbit model for HTLV-
1 infection providing a metric to monitor clinical status of the infected animals as well as a means
for the testing of treatment to combat infection. In some cases proviral load in blood did not reflect
organ proviral levels, revealing a limitation of this method for monitoring health status of HTLV-1
infected individuals.
Background
HTLV-I was the first human retrovirus discovered and was
isolated from cell lines derived from patients with cutane-
ous T cell lymphoma or adult T cell leukemia (ATL) [1,2].
Later it was found that a variety of human diseases are
causally associated with HTLV-I infection, including
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tropical spastic paraparesis (TSP) and myelopathy/tropi-
cal spastic paraparesis (HAM/TSP) [3,4].
Previous studies of infected human subjects suggest that
high proviral load is associated with increased tendency to
develop HTLV-I-associated HAM/TSP, while ATL is associ-
ated with extremely high levels of provirus [5-8]. High
proviral load was also found in HTLV-I infected patients
with seborrheic dermatitis and severe anemia [9] and
patients with rheumatoid arthritis or connective tissue
disease [10]. The role of HTLV-I proviral load in the devel-
opment of diseases was studied in asymptomatic carriers
[11], and blood donors [12,13]. Proviral load measure-
ment was also used to evaluate the risk of mother-to-child
transmission of HTLV-I by breast-feeding [14], study the
mortality in HIV-2 and HTLV-I coinfected subjects [15],
monitor disease activity in HAM/TSP patients [16], count
HTLV-I infected cells in healthy carriers and ATL patients
[17], monitor patients following administration of inter-
feron-α  [18,19] or green tea extract powder [20], deter-
mine the genetic susceptibility to HTLV-I associated
diseases [21-23] as well as determine the influence of
cytokines [24,25].
Rabbit experimental infection has proven to be an excel-
lent model of human HTLV-I infection [26-31]. Research
findings made in rabbits have shed light on transmission
modes, and outcomes in the infected rabbits reflect the
global diversity of clinical manifestations that occur in
HTLV-1 associated diseases, including a variety of cancers,
immunologic diseases, and neurologic disorders [3,4]. As
is the case for human beings, the majority of HTLV-1
infections in rabbits are chronic asymptomatic infections
[28,29]. Data relating proviral load and disease status for
the rabbit infection model would greatly enhance the util-
ity of this experimental system and would allow further
comparison to human infection. In addition the flexibility
afforded by the rabbit model can allow examination of
modes possible for transmission of HTLV-I infection.
In this paper we report adaptation of techniques [32] to
measure HTLV-I proviral load in PBMC and organs of
experimentally infected rabbits. Comparisons were made
among rabbits that were inoculated either with cell-free
virus, whole blood from HTLV-I infected rabbits, or with
an HTLV-I cloned naked DNA. A cohort of infected rabbits
monitored for as long as 2.5 yrs produced several exam-
ples of rabbits with proviral levels exceeding those estab-
lished for asymptomatically infected rabbits; examination
of these revealed clinical abnormalities including neph-
roblastoma and uterine tumors.
Results
Cell-free HTLV-I mediates in vivo infectivity in rabbit 
models
An HTLV-I producing cell line BH24 was derived from
rabbit BH24 inoculated with HTLV-I molecular clone
K30p naked DNA. HTLV-I env protein gp46 was detected
on the surface of BH24 cells and HTLV-I virions isolated
from BH24 cell line have normal size and density (Figure
1). Cell free HTLV-I prepared from BH24 cell culture was
injected intravenously into rabbit TO11 and rabbit TO12
was given whole blood from BH24. After infection was
established rabbit BH42 received blood from TO11 (Fig-
ure 1). After two weeks post inoculation all three rabbits
including TO11, TO12 and BH42 produced HTLV-I anti-
bodies, HTLV-I provirus was detected in their PBMC, and
HTLV-I gag p19 protein was detected in PBMC culture
supernatants (Figure 2). These data indicated that cell-free
HTLV-I can mediate infectivity in rabbits as does infected
blood. In order to determine whether the HTLV-I mutated
during the course of infection and transfer, provirus from
the rabbits (BH24, TO11, TO12, and BH42) was subjected
to sequence analysis at three time points: 8, 12 and 20
months post inoculation. Based on previously observed
sequence differences in HTLV-1 regions selected from
LTR, gag, pol, env and rex genes were analyzed. For each
isolate 4,486 bases were compared and no differences
from the original K30 clone were detected for the period
of observation. These data gave confidence that proviral
load studies may be conducted with little concern for
effects of mutations on primer recognition of the provirus.
Proviral load in PBMC of HTLV-I infected asymptomatic 
rabbits
The proviral load was determined using a real time PCR-
based QPCR assay, in which HTLV-I env gene was selected
as an amplification target. To determine the sensitivity for
this assay, scalar dilutions of K30p clone DNA ranging
from 1 to one billion (109) copies were analyzed. The
results indicate that a positive signal was consistently
detected at HTLV-I DNA concentrations above 1 copy per
ng of DNA. Based on these results the limitation of this
assay was considered to be 1 copy of HTLV-1 proviral
DNA per ng of genomic DNA.
Fifty-seven rabbits infected by different routes and using
different sources of HTLV-I were monitored for proviral
load over a period of 75 weeks at two to four weekly inter-
vals (Figure 3). The highest average proviral load was
observed in PBMC from rabbits inoculated with HTLV-I
infected whole blood and values peaked at 30 weeks post
inoculation. Rabbits injected with HTLV-I naked DNA
produced lower levels of provirus and did not reach max-
imum levels until later than rabbits in the other groups.
Provirus loads were intermediate in rabbits injected with
cell-free virus and reached maximum levels early as didRetrovirology 2005, 2:34 http://www.retrovirology.com/content/2/1/34
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Source and characterization of HTLV-I virions used in this study Figure 1
Source and characterization of HTLV-I virions used in this study. (A) Schematic representation of source and route 
of HTLV-I exposure. Rabbit BH24 was inoculated with HTLV-I clone K30p naked DNA and an HTLV-I producing cell line 
BH24 was derived from rabbit BH24 PBMC. Rabbit BH27 was inoculated with plasmid vector pSV2 DNA as negative control. 
Rabbit TO11 was infected with cell free virus prepared from BH24 cell line supernatant. Rabbits TO13, TO12 and BH42 
received whole blood from rabbits BH27, BH24 and TO11, respectively. (B) Analysis of virus particles produced by cell line 
BH24. Fluorescence-activated cell analysis of cell line BH24 was carried out using antibodies directed against HTLV-I gp46 pro-
tein. Goat anti-mouse Ig labeled with fluorescein isothiocyanate was used as the second reagent. The figure (below) shows 
electro micrographs of particles isolated from supernatant of BH24. The scale bars represent approximately 100 nm. The viri-
ons concentration determined by electro micrographs was 2 × 1010 per ml of BH24 cell culture supernatant. The density of 
particles was 1.16 g / ml measuring by ultracentrifugation on a 20% to 60% sucrose gradient. (Data not shown)
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those given infectious blood. The proviral load peaked
around 30 weeks post infection in blood of all rabbits and
decreased after that time.
Average proviral load measured for HTLV-I infected
asymptomatic rabbits was compared with reported data
for human samples (Table 1). When all data are converted
to the same units, that is, copies of provirus per nanogram
of DNA, a close similarity in levels of provirus is seen
between the experimentally infected rabbits and the
asymptomatic human subjects.
In the course of collecting proviral load data one rabbit
(TO9) showed an unexpected increase from about 3 cop-
ies/ng in a sample taken at 4 months to more than 10 cop-
ies/ng at 8 months post infection with cell-free virus.
Examination of the rabbit revealed an enlarged kidney,
which upon necropsy, was a nephroblastoma. Tissues
Cell-free HTLV-I particles mediate in vivo infectivity Figure 2
Cell-free HTLV-I particles mediate in vivo infectivity. (A) HTLV-I provirus was detected in rabbit PBMC; (B) HTLV-I 
antibodies in rabbit sera were detected using a western blot assay (Genelabs Techologies, Singapore). A goat anti-rabbit IgG 
conjugated with alkaline phosphatase (Santa Cruz Biotechnology, Santa Cruz, CA) was used for rabbit samples instead of goat 
anti-human IgG conjugate provided by the kit. Mo., month post inoculation; +, positive control serum; -, negative control 
serum; rgp46, HTLV-I envelope recombinant protein; gp46, HTLV-I env protein; p19 and p24, HTLV-I gag proteins; GD21 spe-
cific HTLV-I and HTLV-II epitope recombinant envelop protein. (C) HTLV-I gag p19 protein was detected in the culture super-
natants of rabbit PBMC taken at one month post inoculation. (D) Schematic representation showing the regions sequenced. 
The target regions were amplified by PCR and purified PCR products served as templates for direct sequencing. Stable trans-
missions of HTLV-I sequence fragments in rabbit BH24, TO11, TO12 and BH42 were observed. No mutation was detected in 
the analyzed LTR, gag, pol, env, and rex regions for the period of observation up to 20 months. The red arrows indicate the 
primers used to amplify an env fragment in real-time QPCR assay.
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selected from rabbit TO9 and tested for provirus revealed
elevated levels in the thymus, spleen and the tumor dis-
sected from the kidney (Figure 4). Proviral load in the non
neoplastic portion of the kidney was 4 times higher than
the rabbit's own blood lymphocytes and 10 times the
average blood value for all the rabbits.
HTLV-I provirus load in rabbit organs and tumor during 
early and chronic phase of infection
In order to determine proviral loads in major organs from
animals infected by different protocols, samples taken at
necropsy were analyzed. Table 2 shows the distributions
of HTLV-I provirus in rabbit organs. In general the levels
in the organs tested were lower than those of the PBMC
taken at the same time. However, there are sporadic
instances of high proviral load in certain samples, (for
example, the thymus, skin and heart samples from BH19
and the spinal cord of T4-9) but no consistent pattern
emerged from this analysis. Rabbit BH76 exhibiting a typ-
ical PBMC proviral load had an increased level of provirus
in its uterus (Table 2). The proviral load within the benign
uterine endometrial tumor collected at necropsy was
greater than adjacent nontumorous uterine
endometrium, by contrast. A somewhat similar
relationship among proviral loads in blood, tumor and
nonneoplastic adjacent endometrium was observed in
rabbit BH25 with a uterine adenocarcinoma (Table 2).
Rabbit T4-9 also harbored a uterine neoplasm, however
the lesion was not within the endometrium, but resided in
the tunica muscularis and was classified as a uterine leio-
myoma. This rabbit was found to have an elevated level of
PBMC provirus, while the proviral load in the tumor was
1.9 copies per ng of DNA. Interestingly this rabbit's spinal
cord showed an unusually high proviral load, which may
have been what the blood value reflected.
The proviral load measurement also provided a means to
track inoculated rabbits infected with HTLV-1 cell lines
known to cause an ATLL-like disease. In the rabbits receiv-
ing a high dose of RH/K34 cells known to result in exper-
imental ATLL, proviral loads observed in the lung, kidney
and thymus were well above the range established for
asymptomatically infected rabbits (Table 3). One of the
two rabbits sampled had high values for liver and spleen
while the same organs of the other were negative for pro-
virus. The thymus, lung, and kidney of both rabbits had
high levels of provirus, consistent with data obtained by
histologic studies of organs from these rabbits with exper-
imental ATLL [30].
Discussion
The present study describes infection of the rabbit with
HTLV-1 by several different modes and compares the
results of infection. In addition the data show that virus
HTLV-I proviral load in PBMCs of asymptomatic rabbits  infected with HTLV-I by different routes Figure 3
HTLV-I proviral load in PBMCs of asymptomatic rab-
bits infected with HTLV-I by different routes. Rabbits 
inoculated with: (1) whole blood (open squares, n = 29), (2) 
cell free virus (solid diamonds, n = 19), and (3) naked K30p 
DNA (open circles, n = 5). Proviral load is present as mean 
and standard errors (error bars). Probability for statistically 
significant: (1) vs. (2), P = 0.05; (1) vs. (3), P < 0.001; (2) vs. 
(3), P < 0.01.
Table 1: Comparison of proviral load in HTLV-I infected 
asymptomatic rabbits and human samples
Subjects Number tested Copies/ng DNA* Ref.
Rabbits inoculated with
Naked K30p DNA 5 1.5
BH24 cell-free virus 19 2.8
Whole blood 29 3.7
pSV2 plasmid DNA 1 0
Human Asymptomatic 
carriers
200 1.8 [5]
15 1.0† [36]
83 2.7† [20]
120 2.4 [12]
Human HAM/TSP 202 12.0 [5]
15 8.8† [36]
91 9 . 9 [ 1 9 ]
Human ATLL 4 47.4† [37]
* The mean or median (†) of proviral loads are present as HTLV-I 
copy number / ng of genomic DNA prepared from PBMC. The rabbits 
samples were collected after 2 months post inoculation. All published 
data were converted to this format on the basis of one ng of genomic 
DNA corresponding to approximately 150 cells.
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sampled at various time post infection retained the
sequence of the original HTLV-1 clone indicating that var-
iations in response to infection cannot be attributed to
virus mutation. The data here show reproducible in vivo
infectivity of rabbits using naked DNA, cell-free virus,
infected cell lines or whole blood obtained from HTLV-1
infected rabbits. As previously reported most infections
were asymptomatic although certain rabbits monitored
for extended periods did develop tumors. An exception to
the asymptomatic infection involved rabbits challenged
with high doses of the infected cell line RH/K34 [30];
these rabbits succumbed to an aggressive leukemia-like
disease within several days.
The assay used to measure provirus load in human
patients was adapted for use in the rabbit model and
levels of HTLV-1 in blood and parenchymal organs were
measured for rabbits infected using different inocula. The
rabbits inoculated with either infected whole blood or
with cell-free virus showed similar levels of proviral load.
In these animals the provirus quickly assumed maximum
values and stayed high for about 30 weeks then dropped
somewhat to levels that were maintained throughout the
period of observation which was up to 70 weeks. A differ-
ent pattern of provirus load was seen in rabbits infected
with naked HTLV-1 DNA clone. Provirus load levels rose
slowly in these animals and after reaching maximum
levels around 30 weeks began to decline. Average provirus
load in the rabbits infected with DNA reached values
approximately half those infected with blood or cell free
virus.
Comparison of the provirus load values observed for the
rabbits were compared to those reported for human sub-
jects infected with HTLV-1. A close correlation with levels
in asymptomatic infected humans was seen. Levels in rab-
bits infected using whole infected blood were slightly
higher on average than the human average values but in
general the levels suggest that control of infection is simi-
lar in the two species.
Proviral load in rabbit TO9 that developed a renal nephroblastoma Figure 4
Proviral load in rabbit TO9 that developed a renal nephroblastoma. Rabbit TO9 was inoculated with cell-free HTLV-
I prepared from HTLV-I-producing rabbit cell line RH/K30. The rabbit was necropsied at 8 months post inoculation due to 
renomegaly. (A) HTLV-I proviral load was determined in PBMC, selected organs, and in both neoplastic (tumor) and non-neo-
plastic (kidney) regions of the kidney (B) Rabbit kidney, gross photograph of nephroblastoma.
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In several incidents the provirus level rose in an unex-
pected manner in infected rabbits. One of these, rabbit
T09, showed an increase in blood level of provirus to over
10 copies per nanogram of DNA which is about 4 times
normal value. Physical examination and subsequent radi-
ograph of the rabbit revealed an enlarged kidney which
upon necropsy was shown to harbor a large tumor. The
tumor was a nephroblastoma and DNA from it had about
20 copies of provirus per ng. Examination of DNA from
lymphoid tissue and the kidney tissue indicated high lev-
els of provirus. In all cases these were considerably greater
than the blood levels of provirus. The kidney levels were
higher than those of the tumor.
Several other rabbits in the study developed signs that
warranted examination and these animals were sacrificed
and their organs examined and provirus load determined.
For most organs the level of provirus was at the limit of
detection and could be dismissed as negative or due to
slight amount of contamination by blood. Exceptions to
this were seen and point to unusual consequences of
infection. For example BH19 had high blood levels and its
skin was shown to harbor exceptionally high provirus
load. It is tempting to speculate that this animal was
enroute to developing cutaneous signs of infection as has
been seen in the rabbit model [31]. Rabbit T4-9 had a pro-
virus load of 6.7 copies per ng at sacrifice and examination
revealed spinal cord and brain with high provirus load. A
neurologic consequence of this infection may be pre-
dicted in patients with HAM [38,39]. Of three rabbits with
uterine tumors one had high levels of provirus in the
tumor tissue whereas two others did not. In the cohort of
infected rabbits four developed tumors (3 uterine and 1
kidney) and of these 2 had elevated blood levels of provi-
rus. While this number of events is too low to draw a con-
clusion about correlation between tumor development
and proviral load it is interesting that examination of
every rabbit with elevated blood provirus revealed either
organ infection or development of a tumor.
Table 2: Distribution of proviral load in PBMC and organs of HTLV-I infected rabbits*
Inoculated with
Naked DNA Cell-free virus Whole blood
ID (Mo.)† BH19(30) BH21(30) BH25(30) T4-9(11) BH69(19) BH76(17) BH89 (18)
PBMC 7.5 3.9 1.4 6.7 1.3 2.2 8.7
Thymus 22.6 0.4 0.6 0.1 0.3 0.5 1.0
Liver 1.3 0.3 0.3 0.3 0.4 1.8 0.8
Spleen 1.6 0.4 0.1 0.3 0.3 1.7 ND
Skin 23.0 0.3 0.2 4.1 0.2 2.3 0.5
Heart 12.7 2.5 0.3 12.0 0.3 3.1 1.9
Lung 1.8 0.8 0.8 ND 0.7 1.5 2.0
Kidney 3.4 0.5 1.6 0.2 0.5 0.9 1.4
Uterus 3.2 3.0 0.3 ND 1.2 5.0 0.5
Spinal cord 1.7 0.2 0.9 50.5 0.4 0.3 1.2
Brain 0.1 0.3 ND 6.9 ND ND ND
Tumor ‡ NA NA 1.8 1.9 NA 11.0 NA
* Proviral load was reported as copy number per ng of genomic DNA. ND, not determined.
† Rabbit identification number (month post inoculation).
‡ Rabbits T4-9 had a uterine leiomyoma, BH76 had benign endometrial dysplasia, and BH25 developed a uterine adenocarcinoma. NA, not 
applicable.
Table 3: Proviral load in rabbits inoculated with RH/34 cells*
Cells inoculated
2 × 106 2 × 108
ID BH121 BH120 BH101
PBMC 0.5 1.0 ND
Thymus 1.6 88.3 26.3
Live 2.5 207.0 0.5
Spleen 0.0 25.7 0.4
Skin 0.1 6.9 4.8
Heart 0.3 7.3 24.5
Lung 5.1 221.6 217.1
Kidney 0.7 213.0 99.6
* Proviral load was reported as copy number per ng of genomic 
DNA. The samples were collected at 96 hours post inoculation. ND, 
not determined.Retrovirology 2005, 2:34 http://www.retrovirology.com/content/2/1/34
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In this study, we successfully used a quantitative assay to
measure the proviral load of HTLV-1 in PBMC and organs
from several cohorts of infected rabbits. Validation of this
adapted methodology strengthens the utility of this
model for the study of human patients with chronic
HTLV-1 infections. Proviral load measurements were
made in rabbits infected by different methods; proviral
loads from this series of animals infected by different
methods documented levels that appeared to stratify
according to source of inoculum. Such findings suggest
potential of this model for study of HTLV-1 transmission
and its relationship to differences in infectious load. In
addition to monitoring rabbits that were asymptomatic
carriers, proviral load was determined in a subset of rab-
bits with ATLL-like disease. Data suggested proviral load
varied according to tissue compartment, to severity of
leukemic infiltration of organs, and to original inoculum
dose. If substantiated in larger studies, assay for proviral
loads in tissue compartments may reveal additional
insight into pathogenesis of lesions in ATLL [12]. Addi-
tionally, preclinical therapeutic strategies and drug effi-
cacy designed to combat retroviral infections can be
monitored in this system with greater confidence by
measuring proviral load status as a response to treatment.
Materials and methods
Animals
The female New Zealand White rabbits were used in this
study. Six rabbits were given four 100 µg intramuscular
injections of HTLV-I clone K30p naked DNA [33] at
biweekly intervals [34]. Twenty-one rabbits were tested
for cell-free virus infectivity by intravenous inoculation
with 1 to 3 ml of virus preparation containing 1 to 5 ×
1012 copies of viral RNA. A total of 30 rabbits received 3.0
ml of whole blood obtained from HTLV-I infected rabbits.
Three rabbits were inoculated with rabbit cell line RH/
K34, which induces lethal leukemia-like disease in rabbit
in high dose inoculation. Infection in rabbits was moni-
tored by the presence of anti-HTLV-1 antibody, virus pro-
duction in PBMC culture, and detection of viral sequences
in PBMC and organs as previously described [34]. The
health status of all rabbits on study was monitored by
physical examination at time of blood drawing.
Cell lines
The RH/K30 and RH/K34 cell lines were derived by infec-
tion of rabbit peripheral blood mononuclear cells using
human HTLV-I infected cell line, MT-2. The BH24 cell line
was derived from a rabbit inoculated with an infectious
HTLV-I molecular clone K30p naked DNA. BH24 cell line
is available for research purposes from the AIDS Research
and Reference Reagent Program (McKesson BioServices,
Germantown, MD)
Preparation of cell-free HTLV-I
Cell-free viruses were prepared from the culture superna-
tant of HTLV-I producing cell lines. Cells and debris were
removed from supernatants by centrifugation at 800 g for
10 min, and then passed through a 0.22 mm filter (Milli-
pore Corporation, Bedford, MA). The filtrates were con-
centrated to15 to 20 fold through a centrifugal filter
device with 100 NMWL membrane (Millipore Corpora-
tion, Bedford, MA). The virus stock preparation was stored
at -80°C until use. The virus quantitation was measured
by a real-time QRT-PCR assay. Thawed virus preparations
lost binding activity within several hours unless kept at
4°C [35]. HTLV-I gag p19 protein was determined by a
commercial ELISA test (Cellular Product Inc. Buffalo, NY).
Preparation of genomic DNA
The PBMC genomic DNAs were isolated from EDTA-
treated blood samples using Wizard Genomic DNA Puri-
fication Kit (Promega Corporation, Madison, WI). The
organ DNAs were prepared using DNeasy Tissue Kit (Qia-
gen, Hilden, Germany).
Quantification of HTL V-I proviral load
Two sequence-specific primers that detect HTLV-I env
region were used to amplify a 185 bp fragment. The
sequences of HTLV-I env primers are: 5'-ATC CAC TTG
GCA CGT CCT ATA-3' (nt 5890–5910, GenBank acces-
sion no. L03561) and 5'-GCA GGA TGA GGG AGT TAT
GTC-3' (nt 6054–6074). The dual-labeled fluorescent
probe was FAM -5'-CTT TAC CCA TCG TTA GCG CTT CCA
GCC CCC-3'-BHQ1 (nt 5954–5983). Rabbit beta-globin
DNA quantitation was performed in parallel on all sam-
ples in order to determine the amount of cellular DNA
present and was used as an endogenous reference to nor-
malize variations due to differences in the PBMC count or
DNA extraction. A 187 bp fragment of the rabbit beta-
globin gene was amplified by forward primer 5'-GGT ATC
CTT TTT ACA GCA CAA C-3' (nt 372–393, GenBank
accession no.V00882) and reverse primer 5'-CAG GTC
CCC AAA GGA CTC G-3' (nt 531–549) in a real-time PCR
assay. The fluorogenic probe used to detect rabbit beta-
globin gene was 5'Quasar 670 - CCT GGG CTG TTT TCA
TTT TCT CAG G - BHO-2, 3' (nt 471–495). Both the prim-
ers and probes were synthesized by a commercial com-
pany (Biosearch Technologies, Inc., Novato, CA)
HTLV-I env and rabbit beta-globin gene fragments were
amplified separately with an Mx3000P Real-Time PCR
System (Stratagene, La Jolla, Calif.) in 50 µl reaction mix-
ture consisting of 10 µl of DNA sample, 25 µl of Brilliant
QPCR Master Mix (containing PCR buffer, SureStart Taq
DNA polymerase) (Stratagene, La Jolla, Calif.), 10 pmol
of each primer, and 5 pmol of TaqMan probe. Thermal
cycling conditions were as follows: 95°C for 10 min, and
45 cycles of 95°C for 30 s, 55°C for 1 min, and 72°C forRetrovirology 2005, 2:34 http://www.retrovirology.com/content/2/1/34
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30 s. Each sample was analyzed in duplicate, and HTLV-I
proviral load was calculated at the copy number of each
per ng of genomic DNA.
List of abbreviations
ATLL, adult T-cell leukaemia/lymphoma
HAM/TSP, HTLV-I -associated myelopathy/ tropical spas-
tic paraparesis
PBMC, peripheral blood mononuclear cells
QPCR, quantitative polymerase chain reaction
QRT-PCR, quantitative reverse transcription-polymerase
chain reaction
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